- Genprex's Reqorsa® Gene Therapy demonstrates promising preclinical results against resistant lung cancer.
- Synergistic effects observed when combining Reqorsa with sotorasib in KRASG12C mutant tumors.
- Research to be presented at AACR 2025 highlights potential for addressing resistance in cancer treatment.
Genprex, Inc. (GNPX, Financial) has announced that an abstract detailing their research collaborators' findings on Reqorsa® Gene Therapy has been published in the Cancer Research Proceedings. This abstract, scheduled for presentation at the 2025 Annual Meeting of the American Association for Cancer Research (AACR), elucidates positive preclinical data for Reqorsa in treating KRASG12C mutant non-small cell lung cancer (NSCLC).
The preclinical study revealed that TUSC2 gene therapy, delivered via Reqorsa, effectively overcomes resistance to sotorasib in KRASG12C mutant NSCLC mouse xenografts. Key findings include a reduction in colony formation in resistant cell lines, increased apoptosis, and decreased organoid viability. The therapy exhibited significant antitumor efficacy when used alone and enhanced results when combined with sotorasib.
The combination therapy, which exploits the multi-mechanistic actions of Reqorsa, signifies potential in extending the clinical benefits of existing KRAS inhibitors by addressing emerging resistance. The data, while preclinical, hint at the possibility of new therapeutic strategies for treating resistant lung cancer.
The research will be highlighted at the AACR Annual Meeting, with a poster presentation scheduled for April 29, 2025, from 2-5 p.m. CT in Chicago.
Genprex's Reqorsa utilizes the TUSC2 tumor suppressor gene to inhibit key cancer growth pathways such as MAPK and mTOR, while also inducing tumor cell death and activating immune responses. The study's preclinical success forms a robust basis for future clinical trials, signifying a step forward in the fight against resistant cancer types.
